1/2 Drug Development and Capacity Building: A UCR/CoH-CCC Partnership

摘要 美国的癌症药物几乎完全由欧洲人开发、测试和优化， 美国人美国药物开发的差异是长期不平等的结果， 在整个药物研发过程中。只有少数基础、转化和临床科学家 是拉丁裔/西班牙裔或黑人/非裔美国人。不到2-5%的试验参与者是拉丁裔/西班牙裔或 黑人/非裔美国人。然而，尽管缺乏数据，美国食品和药物管理局（FDA）还是批准了新药。 美国食品药品监督管理局（FDA），随后规定为拉丁美洲/西班牙裔或黑人/非洲裔美国人患者， 没有足够的测试。这是不可接受的，特别是在这个精准医学倡议（PMI）的时代， 目前，我们的药物是由我们的公民中的一部分人开发和优化的。我们 寻求通过加强加州大学之间的现有伙伴关系， 滨江（UCR）和希望之城综合癌症中心（CoH-CCC）。在P20中，UCR 和CoH-CCC将合作开发必要的资源、基础设施和培训计划， 培养下一代的治疗学研究人员，反映内陆南部的种族多样性 加州。我们预计，我们的P20计划将推动新的合作R 01赠款和K 01和T型 培训赠款。 .

ABSTRACT Cancer drugs in the United States are almost exclusively developed by, tested in, and optimized for European- Americans. Disparities in U.S. drug development are the result of long-standing inequalities that occur throughout the entire drug discovery pipeline. Only a small number of basic, translational and clinical scientists are Latino/Hispanic or Black/African-American. Less than 2-5% of trial participants are Latino/Hispanic or Black/African-American. Yet, in spite of a lack of data, new drugs are approved by the U.S. Food and Drug Administration (FDA) and subsequently prescribed for Latino/Hispanic or Black/African-American patients, without sufficient testing. It is unacceptable, especially in this era of the Precision Medicine Initiative (PMI), that currently our drugs are developed by, and optimized for, only for an exclusive segment of our citizens. We seek to shift this paradigm by strengthening the existing partnership between University of California at Riverside (UCR) and City of Hope Comprehensive Cancer Center (CoH-CCC). In this proposed P20, UCR and CoH-CCC will partner to develop the resources, infrastructure, and training programs necessary to develop the next generation of therapeutics researchers that reflect the ethnic diversity of Inland Southern California. We anticipate that our P20 program will drive new collaborative R01 grants and K01 and T-type training grants. .